ClinicalTrials.gg
Active, not recruitingNCT03433469Updated Mar 30, 2026Results posted

Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

A Phase 2 interventional study of Osimertinib and Therapeutic Conventional Surgery in Stage I Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Cancer and Stage IB Non-Small Cell Lung Cancer, sponsored by University of California, San Francisco. Active, not recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by University of California, San Francisco · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 43 under way, 8 of them phase 3. osimertinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
72nd of 90
27 · median 51
Started
2018
with 12 others
Phase 2
46 of 90
12 open now
Primary completion
2023-01
later than 4 of 42 live
Registered
33rd of 90
by date

Among the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, this one is the 72nd largest by enrollment, is one of 13 that started in 2018, is one of 46 in phase 2, reaches primary completion later than 4 of the 42 other live ones, and was the 33rd registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

20 of the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung are open now, in 7 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About osimertinib

osimertinib: first FDA approval 2015 (TAGRISSO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This phase II trial studies how well osimertinib works in treating participants with stage I-IIIA Epithelial Growth Factor Receptor (EGFR) -mutant non-small cell lung cancer before surgery. Osimertinib may stop the growth of tumor cells by blocking mutant EGFR signaling in cancer cells.

Read the detailed description

PRIMARY OBJECTIVES:

I. To evaluate the efficacy of osimertinib as neoadjuvant therapy in patients with surgically resectable EGFR-mutant non-small cell lung cancer (NSCLC).

SECONDARY OBJECTIVES:

I. To evaluate the safety of osimertinib given as neoadjuvant therapy in early stage EGFR-mutant NSCLC participants.

II. To evaluate whether neoadjuvant osimertinib treatment increases the frequency of tumors that are unresectable due to adverse events or disease progression.

III. To evaluate secondary measures of clinical efficacy in early stage EGFR-mutant NSCLC patients treated with osimertinib induction therapy.

TERTIARY OBJECTIVES:

I. To evaluate long-term measures of efficacy in patients treated with osimertinib neoadjuvant therapy.

II. To explore tissue and cell-free biomarkers that may be predictive of response or primary resistance to osimertinib neoadjuvant therapy.

OUTLINE:

Participants receive osimertinib orally (PO) once daily (QD) on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgical resection of their cancer.

After completion of study treatment, participants are followed up at 30 days then every 3 months for up to 1 year.

03

Conditions studied

  • Stage I Non-Small Cell Lung Cancer
  • Stage IA Non-Small Cell Lung Cancer
  • Stage IB Non-Small Cell Lung Cancer
  • Stage II Non-Small Cell Lung Cancer
  • Stage IIA Non-Small Cell Lung Cancer
  • Stage IIB Non-Small Cell Lung Cancer
  • Stage IIIA Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females >=18 years of age
  • or cytologically confirmed non-small cell lung cancer (NSCLC), performed on a that occurred within the last 90 days. This biopsy can be deferred if the procedure is deemed to represent an unacceptable safety risk to the patient by the Principal Investigator and as long as the patient has a prior biopsy showing non-small cell lung cancer.
  • Documented activating EGFR mutation (Exon 19 deletion, T790M, or L858R) on tumor samples by Clinical Laboratory Clinical Laboratory Improvement Amendments (CLIA)-approved test
  • Patients treated with osimertinib or another EGFR tyrosine kinase inhibitors (TKI) (including erlotinib, afatinib, gefitinib, \& rocelitinib) are eligible if they received no more than 28 days of treatment, and if there is no evidence of grade 2 or greater treatment adverse events possibly related to treatment with the EGFR TKI.
  • Positron emission tomography (PET)-computed tomography (CT) within the last 60 days showing radiographic stage I to IIIa lung cancer (mediastinal staging biopsy is allowed but not required)
  • Brain magnetic resonance imaging (MRI) (or CT if to MRI) within the last 60 days showing no evidence of disease
  • Documentation that the patient is a candidate for surgical resection of their lung cancer by an American Board of Thoracic Surgery certified surgeon
  • The patient must have a tumor size >=1 centimeter (cm) in its longest diameter.
  • (ECOG) Performance Status (PS) of 0-1
  • Any unresolved toxicities from prior therapy greater than (CTCAE) grade 1 at the time of starting study treatment, with the exception of alopecia and grade 2 prior platinumtherapy-related neuropathy is allowed
  • (AST) and alanine aminotransferase (ALT) =\< 2.5 x (ULN)
  • =\< 1.5 x ULN, (Patients with documented Gilbert's syndrome and conjugated bilirubin within the normal range may be allowed into the study; in this event, it will be documented that the patient was eligible based on conjugated bilirubin levels)
  • Potassium and magnesium within normal range, patients may receive supplements to meet this requirement
  • Leukocytes > 3,000/microliter (mcL)
  • >= 9 g/dL, with no blood transfusions in the 28 days prior to study entry
  • > 1,500/mcL
  • > 100,000/mcL
  • (CrCl) > 50 mL/min for patients with serum creatinine (SCr) > 1.5 x upper limit of normal (ULN)
  • Ability to swallow oral medications
  • Women of (WoCBP) must have a negative serum pregnancy test within 3 days prior to the first dose of study treatment and agree to use highly effective , during the study and for 90 days following the last dose of osimertinib

    • Women of childbearing potential (WoCBP): women between menarche and menopause who have not been permanently or surgically sterilized and are capable of procreation
    • Women NOT of childbearing potential: women who are permanently or surgically sterilized or

      • Permanent sterilization includes hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy but excludes bilateral tubal occlusion; tubal occlusion is considered a highly effective method of birth control but does not absolutely exclude possibility of pregnancy; (the term occlusion refers to both occluding and ligating techniques that do not physically remove the oviducts)
    • Women who have undergone tubal occlusion should be managed on trials as if they are of WoCBP (e.g. undergo pregnancy testing etc., as required by the study protocol)
    • Women will be considered postmenopausal if they are amenorrhoeic for 12 months without an alternative medical cause; the following age-specific requirements apply:

      • Women under 50 years old will be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and with luteinizing hormone and follicle-stimulating hormone levels in the postmenopausal range
      • Women over 50 years of age will be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatments
    • Acceptable contraception methods are:

      • Total sexual abstinence (abstinence must be for the total duration of the trial and the follow-up period)
      • Vasectomized sexual partner plus male condom (with participant assurance that partner received post-vasectomy confirmation of azoospermia)
      • Tubal occlusion plus male condom
      • Intra-uterine device - provided coils are copper-banded, plus male condom
      • Intra-uterine system (IUS) levonorgestrel IUS (e.g., Mirena), plus male condom
      • Medroxyprogesterone injections (Depo-Provera) plus male condom
      • Etonogestrel implants (e.g., Implanon, Norplan) plus male condom
      • Normal and low dose combined oral contraceptive pills, plus male condom
      • Norelgestromin / ethinylestradiol transdermal system plus male condom
      • Intravaginal device (e.g., ethinylestradiol and etonogestrel) plus male condom
      • Cerazette (desogestrel) plus male condom (Cerazette is currently the only highly efficacious progesterone based pill)
    • Unacceptable Contraception Methods The following methods are considered not to be highly effective and are therefore not acceptable contraceptive methods:

      • Triphasic combined oral contraceptives
      • All progesterone only pills except, Cerazette
      • All barrier methods, if intended to be used alone
      • Non-copper containing intra-uterine devices
      • Fertility awareness methods
      • Coitus interruptus
  • Men with a female partner of childbearing potential must have either had a prior vasectomy agree to use effective contraception as described in the full protocol for at least 14 days prior to administration of the first dose of study treatment, during the study, and for 90 days following the last dose of osimertinib

Exclusion criteria

Exclusion Criteria:

  • or other central nervous system (CNS)
  • Stage IIIB, or distant metastases (including malignant pleural effusion) identified on PET-CT scan or (PET abnormalities that are negative for on biopsy will be considered on a case by case basis
  • Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required treatment, or any evidence of clinically active interstitial lung disease
  • Patients who are known to be serologically positive for (HIV)
  • Active second malignancy, i.e. patient known to have potentially fatal cancer present for which he/she may be (but not necessarily) currently receiving treatment; patients with a history of malignancy that has been completely treated, with no evidence of that cancer currently, are permitted to enroll in the trial provided all chemotherapy for prior malignancy was completed > 12 months prior and/or bone marrow transplant > 2 years prior
  • Patients who are currently receiving treatment with interval (QTc) prolonging medications or potent inducers, if that treatment cannot be either discontinued or switched to a different medication prior to first day of study treatment. All patients must try to avoid concomitant use of any medications, herbal supplements and/or ingestion of foods with known inducer effects
  • Any of the following cardiac abnormalities or history:

    • Mean resting corrected QT interval (QTc) > 470 msec, obtained from 3 (ECGs), using the screening clinic ECG machine derived QTc value
    • Any abnormalities in rhythm, conduction or morphology of resting ECG e.g. complete left bundle branch block, third degree heart block and second degree heart block
    • Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval
  • Treatment with prohibited medications (concurrent anticancer therapy including chemotherapy, radiation, hormonal treatment [except corticosteroids and megesterolacetate], or immunotherapy) =\< 14 days prior to treatment with osimertinib
  • Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator?s opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol, or known active infection including chronic active , and human immunodeficiency virus (HIV); screening for chronic conditions is not required; patients with chronic hepatitis B virus (HBV) with negative HBV viral load on appropriate antiviral therapy will be permitted, if able to continue appropriate antiviral therapy throughout treatment period
  • Active tuberculosis
  • Signs or symptoms of infection within 2 weeks prior to first day of study
  • Therapeutic oral or intravenous (IV) antibiotics within 2 weeks prior to first day of study treatment:

    • Patients receiving prophylactic antibiotics (eg, to prevent a urinary tract infection or exacerbation) are eligible
  • Class II to IV heart failure as defined by the functional classification system
  • Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or (LVEF) \< 50% must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate, to be eligible
  • Patients who have experienced untreated and/or uncontrolled cardiovascular conditions and/or have symptomatic cardiac dysfunction (unstable angina, congestive heart failure, myocardial infarction within the previous 3 months; coronary angioplasty, or stenting or bypass grafting within the past 6 months; cardiac ventricular arrhythmias requiring medication; any history of second (2nd) or third (3rd) degree atrioventricular conduction defects)
  • Females who are pregnant or breastfeeding
  • Presence of active gastrointestinal (GI) disease (including GI bleeding or ulceration) or other condition that could affect GI absorption (e.g. malabsorption syndrome, history of biliary tract disease), including nausea or vomiting, or chronic GI disease which may affect absorption or tolerance to oral medications
  • History of to active or inactive of osimertinib or drugs with a similar chemical structure or class to osimertinib
  • Involvement in the planning and/or conduct of the study (applies to both investigator staff and/or staff at the study site)
  • Participation in another clinical study with an product during the last 2 months or within five half-lives of the compound, whichever is longer
  • Uncontrolled medical, psychological, familial, sociological, or geographical conditions that interfere with the patient?s safety, ability to provide , or ability to comply with the protocol
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Treatment (osimertinib)

    Participants receive 80mg osimertinib orally, once a day (PO QD) on days 1-28. Treatment repeats every 28 days for a minimum of 1 cycle prior to surgery in the absence of disease progression or unacceptable toxicity. Investigators will have the option to give a second cycle of study drug prior to surgery if clinically indicated. Depending on the timing of the final scans, patients may ultimately receive up to two weeks additional therapy with study drug beyond end of cycle 1 (or cycle 2) while awaiting surgery. Patients then undergo surgical resection of their cancer. No treatment with the study drug will be given after surgery.

    Drug: Osimertinib · Procedure: Therapeutic Conventional Surgery

Interventions

  • Given PO (orally)

    Also known as: AZD-9291, Tagrisso

  • ProcedureTherapeutic Conventional Surgery

    Undergo surgery

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Major Pathological Response (MPR)

    Tumors that exhibit =\< 10% viable tumor will meet the criteria for a major pathological response. MPR will be determined in patients who receive at least one dose of study drug and become ineligible for surgery either because of disease progression or adverse event will be deemed not to have achieved MPR. The major pathological response rate will be reported with 95% confidence intervals.

    Time frame: Up to 1 year

Secondary outcomes

  1. Objective Response Rates (ORR)

    The percentage of participants with a best overall response rate of complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria and by investigator's assessment will be determined from the time of treatment until surgery. The frequency and percentages of patients with a best ORR of CR, PR, SD, or PD will be determined. The ORR for each response type will be reported with 95% confidence intervals.

    Time frame: Up to 70 days

  2. Mean Disease-free Survival (DFS)

    DFS will be calculated as 1+ the number of days from date of surgical resection to documented radiographic relapse/progression or death due to any cause over a period of 60 months. The Kaplan-Meier analysis will be used to calculate the median DFS with 95% confidence interval.

    Time frame: Up to 5 years

  3. Disease-free Survival Rate (DFS)

    DFS will be calculated as 1+ the number of days from date of surgical resection to documented radiographic relapse/progression or death due to any cause over a period of 60 months. The 5-year DFS rate will be calculated as the percentage of patients who are disease free at 5 years. This will be calculated using the Kaplan-Meier method

    Time frame: Up to 5 years

  4. Overall Survival (OS)

    5-year OS rate will be calculated using the Kaplan-Meier method . OS will be defined as the 1+ the number of days from surgical resection to death due to any cause over a period of 60 months. The Kaplan-Meier analysis will be used to calculate the median OS with 95% confidence interval.

    Time frame: Up to 5 years

  5. Median Percentage Change in Tumor Burden (Depth of Response)

    Depth of response (DpR) will be defined as the percentage change in tumor burden by RECIST criteria at best response versus baseline imaging. DpR will be summarized using descriptive statistics.

    Time frame: Up to 1 year

  6. Pathologic Complete Response Rate (pCR)

    The pCR is defined as absence of (0%) viable tumor present histologically in the resected tumor specimen

    Time frame: Up to 1 year

  7. Percentage of Participants With of Treatment-related Adverse Events (AEs)

    The percentage of participants with treatment-related adverse events will be reported. Adverse events will be classified according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

    Time frame: Up to 1 year

  8. Percentage of Participants Unable to Undergo Surgical Resection

    Rate of conversion from operable to non-operative will be recorded as rate of patients initially assessed as surgically resectable, who are subsequently unable to undergo surgical resection due to either treatment-related adverse events (AEs) or disease progression.

    Time frame: Up to 70 days

  9. Percentage of Surgical Complications

    Rate of surgical complications occurring prior to the end of treatment visit will be reported

    Time frame: Up to 1 year

07

Results

Posted Jan 18, 2024

Participant flow

Participant flow — Overall Study
MilestoneTreatment (Osimertinib)
Started27
Completed27
Not completed0

Outcome measures

PrimaryPercentage of Participants With a Major Pathological Response (MPR)

Tumors that exhibit =\< 10% viable tumor will meet the criteria for a major pathological response. MPR will be determined in patients who receive at least one dose of study drug and become ineligible for surgery either because of disease progression or adverse event will be deemed not to have achieved MPR. The major pathological response rate will be reported with 95% confidence intervals.

Time frame:
Up to 1 year
Reported as:
Number · percentage of participants
Percentage of Participants With a Major Pathological Response (MPR)
percentage of participantsTreatment (Osimertinib)
Percentage of Participants With a Major Pathological Response (MPR)14.8 (5.9 to 32.5)
SecondaryObjective Response Rates (ORR)

The percentage of participants with a best overall response rate of complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria and by investigator's assessment will be determined from the time of treatment until surgery. The frequency and percentages of patients with a best ORR of CR, PR, SD, or PD will be determined. The ORR for each response type will be reported with 95% confidence intervals.

Time frame:
Up to 70 days
Reported as:
Number · percentage of participants
Objective Response Rates (ORR)
percentage of participantsTreatment (Osimertinib)
Complete Response (CR)0 (0 to 12.5)
Partial Response51.9 (34 to 69)
Stable Disease44.4 (27.6 to 62.7)
Progressive Disease3.7 (0.2 to 18.3)
SecondaryMean Disease-free Survival (DFS)

DFS will be calculated as 1+ the number of days from date of surgical resection to documented radiographic relapse/progression or death due to any cause over a period of 60 months. The Kaplan-Meier analysis will be used to calculate the median DFS with 95% confidence interval.

Time frame:
Up to 5 years

Results for this outcome have not been posted.

SecondaryDisease-free Survival Rate (DFS)

DFS will be calculated as 1+ the number of days from date of surgical resection to documented radiographic relapse/progression or death due to any cause over a period of 60 months. The 5-year DFS rate will be calculated as the percentage of patients who are disease free at 5 years. This will be calculated using the Kaplan-Meier method

Time frame:
Up to 5 years

Results for this outcome have not been posted.

SecondaryOverall Survival (OS)

5-year OS rate will be calculated using the Kaplan-Meier method . OS will be defined as the 1+ the number of days from surgical resection to death due to any cause over a period of 60 months. The Kaplan-Meier analysis will be used to calculate the median OS with 95% confidence interval.

Time frame:
Up to 5 years

Results for this outcome have not been posted.

SecondaryMedian Percentage Change in Tumor Burden (Depth of Response)

Depth of response (DpR) will be defined as the percentage change in tumor burden by RECIST criteria at best response versus baseline imaging. DpR will be summarized using descriptive statistics.

Time frame:
Up to 1 year
Reported as:
Median · percent change
Median Percentage Change in Tumor Burden (Depth of Response)
percent changeTreatment (Osimertinib)
Median Percentage Change in Tumor Burden (Depth of Response)-32 (-40 to -18)
SecondaryPathologic Complete Response Rate (pCR)

The pCR is defined as absence of (0%) viable tumor present histologically in the resected tumor specimen

Time frame:
Up to 1 year
Reported as:
Number · percentage of participants
Pathologic Complete Response Rate (pCR)
percentage of participantsTreatment (Osimertinib)
Pathologic Complete Response Rate (pCR)0 (0 to 12.5)
SecondaryPercentage of Participants With of Treatment-related Adverse Events (AEs)

The percentage of participants with treatment-related adverse events will be reported. Adverse events will be classified according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

Time frame:
Up to 1 year
Reported as:
Number · percentage of participants
Percentage of Participants With of Treatment-related Adverse Events (AEs)
percentage of participantsTreatment (Osimertinib)
Percentage of Participants With of Treatment-related Adverse Events (AEs)100
SecondaryPercentage of Participants Unable to Undergo Surgical Resection

Rate of conversion from operable to non-operative will be recorded as rate of patients initially assessed as surgically resectable, who are subsequently unable to undergo surgical resection due to either treatment-related adverse events (AEs) or disease progression.

Time frame:
Up to 70 days
Reported as:
Number · percentage of participants
Percentage of Participants Unable to Undergo Surgical Resection
percentage of participantsTreatment (Osimertinib)
Percentage of Participants Unable to Undergo Surgical Resection11.1 (3.9 to 28.1)
SecondaryPercentage of Surgical Complications

Rate of surgical complications occurring prior to the end of treatment visit will be reported

Time frame:
Up to 1 year
Reported as:
Number · percentage of participants
Percentage of Surgical Complications
percentage of participantsTreatment (Osimertinib)
Percentage of Surgical Complications62.5 (42.7 to 78.8)

Adverse events

Collected over Up to 1 year. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment (Osimertinib)4/27 (14.8%)3/27 (11.1%)27/27 (100%)
Most frequent serious events
Most frequent serious events
EventTreatment (Osimertinib)
Atrial fibrillationCardiac disorders1/27
DyspneaRespiratory, thoracic and mediastinal disorders1/27
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders1/27
Most frequent other events
Showing 10 of 26
Most frequent other events
EventTreatment (Osimertinib)
DiarrheaGastrointestinal disorders13/27
FatigueGeneral disorders8/27
NauseaGastrointestinal disorders7/27
CoughRespiratory, thoracic and mediastinal disorders6/27
Dry SkinSkin and subcutaneous tissue disorders5/27
DyspneaRespiratory, thoracic and mediastinal disorders5/27
Dry mouthGastrointestinal disorders4/27
Abdominal distensionGastrointestinal disorders3/27
Abdominal painGastrointestinal disorders3/27
Skin and subcutaneous tissue disorders - OtherSkin and subcutaneous tissue disorders3/27

Baseline characteristics

Age, Customized
Age, Customized(Participants)Treatment (Osimertinib)
30-39 years old1
40-49 years old2
50-59 years old4
60-69 years old8
70-79 years old9
80-89 years old3
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Treatment (Osimertinib)
Female20
Male6
Not reported/Unknown/Declined to State1
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment (Osimertinib)
Hispanic or Latino1
Not Hispanic or Latino26
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment (Osimertinib)
American Indian or Alaska Native0
Asian11
Native Hawaiian or Other Pacific Islander0
Black or African American0
White15
More than one race0
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(Participants)Treatment (Osimertinib)
United States27
08

Study locations

3 sites
09

References and documents

Publications

  • Blakely CM, Urisman A, Gubens MA, Mulvey CK, Allen GM, Shiboski SC, Rotow JK, Chakrabarti T, Kerr DL, Aredo JV, Bacaltos B, Gee M, Tan L, Jones KD, Devine WP, Doebele RC, Aisner DL, Patil T, Schenk EL, Bivona TG, Riess JW, Coleman M, Kratz JR, Jablons DM. Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study. J Clin Oncol. 2024 Sep 10;42(26):3105-3114. doi: 10.1200/JCO.24.00071. Epub 2024 Jul 19. PubMed 39028931 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Jan 2023, 54 months.

Results were first posted in Jan 2024, 11 months after primary completion.

Of 729 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's 54 months is close to that.

Counting every sponsor, half of 1,046 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2018
First posted
Feb 14, 2018
StartActual
Jul 31, 2018
Primary completionActual
Jan 31, 2023
CompletionEst.
Sep 30, 2027
Results first posted
Jan 18, 2024
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03433469
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Feb 14, 2018
Start date
Jul 31, 2018
Primary completion
Jan 31, 2023
Completion
Sep 30, 2027 (estimated)
Results posted
Jan 18, 2024
Last update
Mar 30, 2026

Study contacts

Collin Blakely, MD, PhD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osimertinib

Start the discussion